TMC278 Powder for Reconstitution with Water-Soluble Polymers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV treatment therapies face challenges such as drug resistance and dosing difficulties, particularly in pediatric patients, where traditional dosage forms like pills and capsules lack flexibility and are unsuitable for young children and infants, and the NNRTI TMC278 has poor water solubility, limiting its effective administration as a powder for reconstitution.
Innovation Solution
A powder formulation of TMC278 dispersed in water-soluble polymers like polyvinylpyrrolidone, copolymers of vinylpyrrolidone and vinyl acetate, hydroxyalkyl alkylcellulose, and poloxamer, which can be mixed with water to create a supersaturated solution for improved solubility and administration, suitable for pediatric and adult patients with swallowing difficulties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If TMC278 is formulated as traditional pills or capsules, then the drug can be administered to adults, but it lacks dosing flexibility and is unsuitable for pediatric patients and infants
Solution Approach 1:
The invention transforms the static fixed-dose tablet into a dynamic reconstitutable powder system where the dosage can be adjusted by varying the amount of powder mixed with water. This allows the same formulation to serve multiple patient populations (infants, children, adults) with different dosing requirements, achieving both dosing flexibility and administration suitability.
Solution Approach 2:
The invention changes the physical form parameter from solid tablet to powder for reconstitution. This parameter change enables flexible dosing by allowing the practitioner to measure different amounts of powder and mix with varying volumes of water, thereby adapting the dosage to pediatric and adult patients while maintaining ease of administration through liquid form.
2Quantity of substance
If TMC278 is converted to acid-addition salt form, then water solubility increases, but the low pH makes it unattractive for pediatric applications
Solution Approach 1:
The invention uses water-soluble polymers as intermediaries to solubilize TMC278 base without requiring conversion to acid salts. The polymer acts as a mediator that enhances water solubility through molecular complexation while maintaining a neutral pH, thereby eliminating the harmful low-pH effect while preserving improved solubility.
Solution Approach 2:
The invention creates a composite material system where TMC278 base is combined with water-soluble polymers (such as polyvinylpyrrolidone, hydroxypropyl methylcellulose, or poloxamer). This composite approach achieves enhanced water solubility through the polymer component while the TMC278 base maintains its neutral pH characteristics, making it suitable for pediatric applications.
3Adaptability or versatility
If TMC278 base is used in powder form, then pediatric applications become feasible, but water solubility remains poor limiting effective uptake
Solution Approach 1:
The invention formulates TMC278 base as a composite material with water-soluble polymers. The polymer component provides the necessary water solubility enhancement while the TMC278 base maintains its suitability for pediatric applications. The composite structure allows the powder to be easily administered to children and infants while achieving effective drug dissolution and uptake.
Solution Approach 2:
The water-soluble polymer serves as an intermediary substance that bridges the gap between TMC278 base and water. The polymer molecules interact with TMC278 base to form soluble complexes, enabling effective dissolution and uptake while preserving the neutral pH and pediatric suitability of the base form.
4Reliability
If multiple anti-HIV agents are administered separately, then each drug can be optimized, but the pill burden increases and compliance decreases
Solution Approach 1:
The invention merges multiple anti-HIV agents into a single reconstitutable powder formulation. Each active ingredient (such as TMC278 combined with other antiretrovirals) is incorporated into the same polymer matrix, allowing all drugs to be administered together in one dose. This reduces pill burden and improves compliance while maintaining the optimized dosing of each individual agent.
Solution Approach 2:
The invention creates a universal dosage form that can accommodate multiple anti-HIV agents with different properties. The reconstitutable powder system serves multiple functions: it provides flexible dosing for different patient populations, improves compliance through single-administration regimens, and maintains the pharmacological optimization of each individual drug through separate formulation control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The powder formulation provides flexible dosing, effective therapeutic concentrations, and reduced pill burden, enhancing patient compliance and HIV treatment efficacy by maintaining viral suppression with improved bioavailability compared to traditional tablet formulations.
Implementation Method 1
TMC278, dispersed in a water-soluble polymer selected from polyvinylpyrrolidone, a copolymer of vinylpyrrolidone and vinyl acetate, a hydroxyalkyl alkylcellulose, and a poloxamer, to be mixed with water
Implementation Method 2
a supersaturated solution of TMC278 and a water-soluble polymer selected from polyvinylpyrrolidone, a copolymer of vinylpyrrolidone and vinyl acetate, a hydroxyalkyl alkylcellulose, and a poloxamer, in an aqueous medium
Data Source
Figure 1
AI summary
This invention relates to powders for reconstitution comprising the NNRTITMC278 dispersed in certain water-soluble polymers, which can be used in the treatment of HIV infection.